theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Internal Medicine

General Rheumatology   

Questions discussed in this category


In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Obinutuzumab in Lupus Nephritis
2 Answers available
7510


Papers discussed in this category


Arthritis and rheumatism, 2012-04
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Ann Rheum Dis, 2013 Jun 05
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Annals of the rheumatic diseases, 2021 Oct 06
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

The New England journal of medicine, 2025 Feb 07
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.

Related Topics in Internal Medicine

  • Psychiatry
  • Dermatology
  • Hematology
  • Infectious Disease
  • Cardiology
  • General Psychiatry
  • General Outpatient Psychiatry
  • Primary Care
  • General Infectious Disease
  • Rheumatology

Copyright © 2025 theMednet
All Rights Reserved.